Effect of Oral Sildenafil With Digital Therapeutic Iontophoresis of Sodium Nitroprussiate in Healthy Volunteers (INFLUX-VS)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
University Hospital, Grenoble
ClinicalTrials.gov Identifier:
NCT00710099
First received: July 2, 2008
Last updated: October 5, 2011
Last verified: October 2011
  Purpose

Iontophoresis is a employed to facilitate drug absorption without systemic effect. This study investigates cutaneous microcirculation when we associate sildenafil per os with SNP via iontophoresis.


Condition Intervention
Healthy
Drug: sildenafil
Drug: nitroprussiate iontophoresis

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Effect of Oral Sildenafil With Digital Therapeutic Iontophoresis of Sodium Nitroprussiate on Cutaneous Blood Flow in Healthy Volunteers

Resource links provided by NLM:


Further study details as provided by University Hospital, Grenoble:

Primary Outcome Measures:
  • variation of conductance of nitroprussiate iontophoresis associated with oral sildenafil [ Time Frame: one hour ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • To assess the effect of oral sildenafil (50 mg and 100 mg) on skin microvascular reactivity to local cooling, on the forearm and the finger [ Time Frame: one hour ] [ Designated as safety issue: No ]

Estimated Enrollment: 40
Study Start Date: July 2008
Study Completion Date: June 2011
Primary Completion Date: June 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1 Drug: sildenafil
systemic absorption of sildenafil
Active Comparator: 2
SNP iontophoresis
Drug: nitroprussiate iontophoresis
nitroprussiate iontophoresis

Detailed Description:

The main outcome is the proof of concept of effect of systemic absorption sildenafil on cutaneous microcirculation associated with SNP iontophoresis.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Age over 18
  • No significant medical history

Exclusion Criteria:

  • Age under 18
  • Period of exclusion for an other study
  • Pregnancy
  • Breast feeding
  • Severe disease
  • Cigarette smoking
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00710099

Locations
France
Clinical Researsh Centre
Grenoble, Isere, France, 38043
Sponsors and Collaborators
University Hospital, Grenoble
Investigators
Principal Investigator: Jean-Luc CRACOWSKI, MD Institut National de la Santé Et de la Recherche Médicale, France
  More Information

Publications:
Responsible Party: University Hospital, Grenoble
ClinicalTrials.gov Identifier: NCT00710099     History of Changes
Other Study ID Numbers: DCIC/08/08
Study First Received: July 2, 2008
Last Updated: October 5, 2011
Health Authority: France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)

Keywords provided by University Hospital, Grenoble:
iontophoresis
cutaneous microcirculation
sildenafil
Healthy volunteers

Additional relevant MeSH terms:
Sildenafil
Cardiovascular Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Phosphodiesterase 5 Inhibitors
Phosphodiesterase Inhibitors
Therapeutic Uses
Urological Agents
Vasodilator Agents

ClinicalTrials.gov processed this record on October 21, 2014